AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04153656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reading and studying Spiritual Flow
Description: The Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey. Two months after the first survey, the Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey.
Study NCT04058912 — intervention group
Intervention type: GENETIC
Intervention: PTEN-AKT-FOXO3 Gene Expression
Description: In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
Study NCT02498821 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sherlock 3CG® TCS
Description: The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
Study NCT00620919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1068 (Synthetic Human Secretin)
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Study NCT04049227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT02498821 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripherally Inserted Central Catheter (PICC)
Description: A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
Study NCT04049227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT00525304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program for chronic illness
Description: Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
Study NCT01484002 — intervention group
Intervention type: DEVICE
Intervention: Total hip arthroplasty
Description: Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
Study NCT02106156 — intervention group
Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a
Description: Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
Study NCT02494011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercise
Description: mobilization stretching exercise
Study NCT02494011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Russian current stimulation
Description: stimulation to wrist flexors for 15 minutes
Study NCT02494011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed kinetic chain exercise
Description: wall press exercise plyometric exercise
Study NCT03901300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fundamental Motor Skills App
Description: Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.
Study NCT03901300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured Physical Activity App
Description: Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
Study NCT03593629 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 6-month PrEP + blood-based HIV self-test
Description: Participants receive 6-month PrEP supply plus two blood-based HIV self-tests (Atomo Diagnostics Blood-Based HIV-1 Self-Testing Kit) for quarterly HIV testing.
Study NCT03593629 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 6-month PrEP + oral fluid HIV self-test
Description: Participants receive 6-month PrEP supply plus two oral fluid HIV self-tests (OraQuick Oral Fluid-based HIV-1 Self-Testing Kit) for quarterly HIV testing.
Study NCT04490915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinecerfont
Description: CRF1-receptor antagonist
Study NCT02106156 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin administered according to corresponding summary of product characteristics (SmPC).
Study NCT00455637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study NCT01068561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of autologous bone marrow stem cells
Description: One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
Study NCT03384056 — intervention group
Intervention type: DEVICE
Intervention: Self Pressurized Airway Device with Blocker
Description: used in adult low risk females undergoing elective gynecological operations
Study NCT03384056 — intervention group
Intervention type: DEVICE
Intervention: Proseal Laryngeal Mask Airway
Description: used in adult low risk females undergoing elective gynecological operations.
Study NCT03059290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neolix file
Description: first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
Study NCT02765841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomitapide
Study NCT03319199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SLIM WATER
Description: 2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
Study NCT03319199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - water
Description: for a duration of 16 weeks
Study NCT02882607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mzanga Samala Moyo Wako ([Mzanga] Peer Groups
Description: 8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
Study NCT04482465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample
Description: blood sample to determine omega6/omega 3 ratio, EPA, DHA, zinc, cupric oxide, vitamine D
Study NCT04313855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SMS in the early detection of postoperative neuropathic pain
Description: 7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks.
Study NCT03247933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine: Maintenance Respiratory Rehabilitation
Description: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance respiratory rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~They will be in their homes doing the program of treatment prescribed by the physician. They will be provided with the material that is needed: 1 static bicycle, 2-weights / cufflinks, 3-device mobile (smartphone/PDA) + Pulse Oximeter.~The patient must send the exercises every day that are scheduled training exercises once have been completed.
Study NCT01923753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerosure at 15 Hz
Description: Active Aerosure HFAO device operating at lower frequency
Study NCT01923753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerosure at 25 Hz
Description: Active Aerosure HFAO device operating at higher frequency
Study NCT01923753 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Aerosure
Description: Deactivated but identical Aerosure HFAO device
Study NCT01381653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: HIV prevention intervention
Description: Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
Study NCT02973685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.
Study NCT02973685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
Study NCT02973685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: oxaliplatin,leucovorin and 5-FU
Study NCT02973685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE Drug Protocol
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)
Study NCT03427944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Dobesilate group
Description: Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
Study NCT03427944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Treatment group
Description: Conventional treatment were used to treat patients with chronic renal failure.
Study NCT02304211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
Study NCT02304211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
Study NCT03886935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Study NCT04140877 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Visu
Description: An experimental (test) virtual reality display
Study NCT01419093 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: 5 A communication intervention
Description: This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on \[feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
Study NCT00462228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
Study NCT00462228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
Study NCT01958450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: acne scar treatment using Er:YAG laser
Study NCT01958450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar radiofrequency with diode laser
Description: acne scar treatment with bipolar radiofrequency combined with diode laser
Study NCT04461379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: A single dose BCG vaccine intradermally (deltoid region of the right arm) 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis . (Tokio 172 strain)
Study NCT04461379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose intradermally ((deltoid region of the right arm) 0.1 ml of NaCl 0.9% solution
Study NCT04490915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crinecerfont
Description: CRF1-receptor antagonist
Study NCT04490915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active dosage form
Study NCT02110693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interviewer and tablet administration of the TAPS Tool
Description: All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
Study NCT04444050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days
Study NCT00361530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Study NCT03304457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 10mg once daily orally for 6 weeks
Study NCT03304457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 80mg once daily orally for 6 weeks
Study NCT03192579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPA and high dose rosuvastatin
Description: After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
Study NCT03192579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard dose rosuvastatin
Description: After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
Study NCT02101008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: disulfiram and chelated zinc
Study NCT02772783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high GI meal
Description: High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of \~90 is achieved by using corn syrup as a carbohydrate source.
Study NCT02772783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low GI meal
Description: High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of \~40 is achieved by using uncooked corn starch as a carbohydrate source.
Study NCT02772783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: euglycemic insulin clamp
Description: Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
Study NCT02772783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: euglycemic insulin clamp
Description: Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
Study NCT02772783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primed-variable insulin infusion
Description: A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are > 400 mg/dl or \< 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
Study NCT04026789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Same-day-start
Description: Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
Study NCT04026789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delay-for-diagnosis
Description: Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
Study NCT01374698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325 mg
Study NCT03246074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg bid and Paclitaxel
Description: Drug: Fostamatinib (oral; 100 mg bid)~Drug: Paclitaxel (60-80 mg/m2)
Study NCT03246074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 150 mg bid and Paclitaxel
Description: Drug: Fostamatinib (oral; 150 mg bid)~Drug: Paclitaxel (60-80 mg/m2)
Study NCT03246074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 200 mg bid and Paclitaxel
Description: Drug: Fostamatinib (oral; 200 mg bid)~Drug: Paclitaxel (60-80 mg/m2)
Study NCT00956189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride
Description: Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
Study NCT00956189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.